Intech Biopharm Corporation (6461)

Profile

https://www.intechbiopharm.com

Intech Biopharm Corporation is a specialty pharmaceutical company established in 2010 and headquartered in Taipei, Taiwan. The company focuses on the development, manufacturing, and commercialization of inhalation-based medicines, primarily targeting respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). Intech Biopharm distinguishes itself through expertise in pressurized metered dose inhalers (pMDI) and dry powder inhalers (DPI), leveraging its iLEF (inhaled low ethanol formulation) platform to deliver effective respiratory therapies. The company has brought products like Duasma and Synvent to market and maintains a robust pipeline intended for global distribution, including drugs in late-stage clinical trials. Its manufacturing facility adheres to stringent regulatory standards set by the US FDA and EU GMP, positioning the firm as a leader in high-barrier generic and combination drug production. Intech Biopharm plays a significant role in the healthcare sector by supplying advanced respiratory treatments domestically and abroad, aiming to advance the quality and accessibility of respiratory care worldwide.